White House: US taxpayers are subsidizing international drug prices

(By Emily Rappleye for Becker’s Hospital Review)

Top-selling pharmaceuticals are priced much lower abroad, leaving U.S. taxpayers and patients to foot the bill for biopharmaceutical research and development, according to the findings of a recent report from the White House Council of Economic Advisers.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.